Patent ID: 6506790
Filing Date: 2003-01-14
Classification: A61K,A61P,C07D

Abstract:
A method of treating a CCR5-mediated disease state in mammals which comprises administering to the mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein:R1, R2, R6, and R7 are independently hydrogen or C1-6alkyl; R3 is hydrogen or hydroxy; R4 is hydrogen or C1-6alkyl; R5 is hydrogen, C1-6alkyl, C3-6cycloalkyl, or aralkyl; or, NR4R5 may form a heterocyclic ring having 5-, 6-, or 7-members, optionally containing one of oxygen, sulfur, or NR8; R8 is hydrogen, C1-6alkyl, or aralkyl; X is hydrogen or one or more of C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C5-6cycloalkenyl, aralkyl, aryl, CH2NR9R10, CH2OR11, COR11, CONR9R10, CO2R11,cyano, trifluoromethyl, NR9R10, NR9COR11, NR9CONR9R10, NR9CO2R12, NR9SO2R13, nitro, hydroxy, C1-6alkoxy, OC(O)R11, OC(O)NR9R10, SR14, SOR13, SO2R13, SO2NR9R10 or halogen; R9 and R10 are independently hydrogen, C1-6alkyl, aralkyl or aryl; or NR9R10 forms a heterocyclic ring having 5- or 6-members, optionally containing one oxygen, sulfur, or NR8; R11 is hydrogen, C1-6alkyl, aralkyl, aryl, or trifluoromethyl; R12 is C1-6alkyl, aralkyl, aryl, or trifluoromethyl; R13 is C1-6alkyl, aralkyl, aryl, or trifluoromethyl; R14 is hydrogen, C1-6alkyl, aralkyl, aryl, or trifluoromethyl; and  is a single or a double bond.